^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    UCD19 CAR T Cells

    i
    Other names: UCD19 CAR T Cells, CD19CAR-CD3zeta-4-1BB-expressing allogeneic T-lymphocyte cells
    Associations

    News

    Trials
    Company:
    University of Colorado
    Drug class:
    CD19-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    9d
    Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL) (clinicaltrials.gov)
    P1, N=11, Active, not recruiting, University of Colorado, Denver | Trial completion date: Dec 2023 --> Dec 2024
    Trial completion date
    |
    CD19 (CD19 Molecule)
    |
    CD19 positive • CD19 expression
    |
    UCD19 CAR T Cells
    4ms
    UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL (clinicaltrials.gov)
    P1/2, N=50, Recruiting, University of Colorado, Denver
    Trial completion date • Trial primary completion date • CAR T-Cell Therapy
    |
    CD19 (CD19 Molecule)
    |
    CD19 expression
    |
    UCD19 CAR T Cells
    7ms
    Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL) (clinicaltrials.gov)
    P1, N=11, Active, not recruiting, University of Colorado, Denver | Trial primary completion date: Dec 2023 --> Mar 2023
    Trial primary completion date
    |
    CD19 (CD19 Molecule)
    |
    CD19 positive • CD19 expression
    |
    UCD19 CAR T Cells
    10ms
    Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL) (clinicaltrials.gov)
    P1, N=11, Active, not recruiting, University of Colorado, Denver | Trial primary completion date: Dec 2022 --> Dec 2023
    Trial primary completion date
    |
    CD19 (CD19 Molecule)
    |
    CD19 positive • CD19 expression
    |
    UCD19 CAR T Cells
    10ms
    UCD19 CAR T Therapy in Adults With B-ALL and MRD Positivity in CR1 (clinicaltrials.gov)
    P1; Not yet recruiting --> Recruiting | Trial completion date: Apr 2026 --> Jul 2027 | Initiation date: Dec 2023 --> Jul 2023 | Trial primary completion date: Apr 2025 --> Jul 2025
    CAR T-Cell Therapy • Trial completion date • Trial primary completion date • Enrollment open • Trial initiation date • Minimal residual disease
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
    |
    clonoSEQ
    |
    UCD19 CAR T Cells
    over1year
    UCD19 CAR T Therapy in Adults With B-ALL and MRD Positivity in CR1 (clinicaltrials.gov)
    P1, N=14, Not yet recruiting, University of Colorado, Denver | Initiation date: Dec 2022 --> Dec 2023
    Trial initiation date • CAR T-Cell Therapy • Minimal residual disease
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • CD19 (CD19 Molecule)
    |
    UCD19 CAR T Cells
    over1year
    UCD19 CAR T Therapy in Adults With B-ALL and MRD Positivity in CR1 (clinicaltrials.gov)
    P1, N=14, Not yet recruiting, University of Colorado, Denver
    New P1 trial • CAR T-Cell Therapy • Minimal residual disease
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • CD19 (CD19 Molecule)
    |
    UCD19 CAR T Cells
    over1year
    Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL) (clinicaltrials.gov)
    P1, N=11, Active, not recruiting, University of Colorado, Denver | Recruiting --> Active, not recruiting | N=20 --> 11
    Enrollment closed • Enrollment change
    |
    CD19 (CD19 Molecule)
    |
    CD19 positive • CD19 expression
    |
    UCD19 CAR T Cells
    over1year
    Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL) (clinicaltrials.gov)
    P1, N=20, Recruiting, University of Colorado, Denver | Trial completion date: Dec 2022 --> Dec 2023
    Trial completion date
    |
    CD19 (CD19 Molecule)
    |
    CD19 positive • CD19 expression
    |
    UCD19 CAR T Cells
    over2years
    UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL (clinicaltrials.gov)
    P1/2, N=50, Recruiting, University of Colorado, Denver | Trial completion date: Jul 2021 --> Jul 2026 | Trial primary completion date: Jun 2021 --> Jun 2026
    Clinical • Trial completion date • Trial primary completion date • CAR T-Cell Therapy
    |
    CD19 (CD19 Molecule)
    |
    CD19 expression
    |
    UCD19 CAR T Cells
    almost3years
    Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL) (clinicaltrials.gov)
    P1, N=20, Recruiting, University of Colorado, Denver | Trial completion date: Mar 2024 --> Dec 2022 | Trial primary completion date: Mar 2024 --> Dec 2022
    Clinical • Trial completion date • Trial primary completion date
    |
    CD19 (CD19 Molecule)
    |
    CD19 positive • CD19 expression
    |
    UCD19 CAR T Cells
    3years
    UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL (clinicaltrials.gov)
    P1/2, N=50, Recruiting, University of Colorado, Denver | Not yet recruiting --> Recruiting
    Clinical • Enrollment open • CAR T-Cell Therapy
    |
    CD19 (CD19 Molecule)
    |
    CD19 expression
    |
    UCD19 CAR T Cells